Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors
Aviceda Therapeutics, a clinical-stage biotech company, has appointed Dr. Emmett T. Cunningham Jr. to its Board of Directors. Dr. Cunningham brings over 20 years of experience as a physician-scientist, healthcare entrepreneur, and investor, previously serving as Senior Managing Director at Blackstone Group.
Throughout his career, Dr. Cunningham has contributed to the FDA approval of ten therapeutics, including notable ophthalmic treatments. He previously held the position of Senior Vice President of Medical Strategy at Eyetech Pharmaceuticals, where he played a key role in developing Macugen®, the first VEGF-A inhibitor approved for specific eye conditions.
The appointment comes as Aviceda prepares to advance AVD-104 into pivotal trials for geographic atrophy, utilizing their proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform aimed at alleviating chronic, non-resolving inflammation.
Aviceda Therapeutics, un'azienda biotech in fase clinica, ha nominato Dr. Emmett T. Cunningham Jr. nel suo Consiglio di Amministrazione. Il Dr. Cunningham porta con sé oltre 20 anni di esperienza come medico-scienziato, imprenditore nel settore sanitario e investitore, avendo precedentemente ricoperto il ruolo di Senior Managing Director presso Blackstone Group.
Nel corso della sua carriera, il Dr. Cunningham ha contribuito all'approvazione da parte della FDA di dieci terapie, comprese importanti trattamenti oftalmici. Ha anche ricoperto la posizione di Senior Vice President of Medical Strategy presso Eyetech Pharmaceuticals, dove ha giocato un ruolo fondamentale nello sviluppo di Macugen®, il primo inibitore VEGF-A approvato per specifiche condizioni oculari.
Questa nomina arriva mentre Aviceda si prepara a portare AVD-104 in prove decisive per l'atrofia geografica, utilizzando la loro piattaforma di nanotechnology proprietaria High Affinity Ligands of Siglecs (HALOS™), mirata ad alleviare l'infiammazione cronica e non risolvente.
Aviceda Therapeutics, una empresa biotecnológica en etapa clínica, ha nombrado al Dr. Emmett T. Cunningham Jr. en su Junta Directiva. El Dr. Cunningham aporta más de 20 años de experiencia como médico-científico, emprendedor en el sector salud e inversor, habiendo ocupado previamente el cargo de Director General Senior en Blackstone Group.
A lo largo de su carrera, el Dr. Cunningham ha contribuido a la aprobación por parte de la FDA de diez terapias, incluyendo tratamientos oftálmicos notables. Anteriormente, ocupó el cargo de Vicepresidente Senior de Estrategia Médica en Eyetech Pharmaceuticals, donde desempeñó un papel clave en el desarrollo de Macugen®, el primer inhibidor de VEGF-A aprobado para condiciones oculares específicas.
El nombramiento se produce mientras Aviceda se prepara para avanzar con AVD-104 en ensayos decisivos para la atrofia geográfica, utilizando su plataforma de nanotecnología propietaria High Affinity Ligands of Siglecs (HALOS™), destinada a aliviar la inflamación crónica y no resolutiva.
Aviceda Therapeutics는 임상 단계의 생명공학 회사로, Dr. Emmett T. Cunningham Jr.을 이사회에 임명했습니다. Cunningham 박사는 20년 이상의 의사-과학자, 의료 기업가 및 투자자로서의 경험을 가지고 있으며, 이전에는 Blackstone Group의 수석 관리 이사로 재직했습니다.
그의 경력 동안 Cunningham 박사는 FDA의 10가지 치료제 승인에 기여했으며, 특히 주목할 만한 안과 치료제를 포함하고 있습니다. 그는 Eyetech Pharmaceuticals에서 의료 전략의 수석 부사장직을 역임하며 특정 안과 질환에 대해 승인된 첫 번째 VEGF-A 억제제인 Macugen®의 개발에 중요한 역할을 했습니다.
이번 임명은 Aviceda가 지리적 위축을 위한 결정적인 시험에 AVD-104를 진전시키기 위해 준비하면서 이루어졌으며, 만성 비해결 염증을 완화하기 위한 독점 High Affinity Ligands of Siglecs (HALOS™) 나노기술 플랫폼을 활용하고 있습니다.
Aviceda Therapeutics, une entreprise biopharmaceutique en phase clinique, a nommé Dr. Emmett T. Cunningham Jr. à son conseil d'administration. Le Dr Cunningham apporte plus de 20 ans d'expérience en tant que médecin-scientifique, entrepreneur en santé et investisseur, ayant précédemment occupé le poste de directeur général senior chez Blackstone Group.
Tout au long de sa carrière, le Dr Cunningham a contribué à l'approbation par la FDA de dix thérapeutiques, y compris des traitements ophtalmiques notables. Il a précédemment occupé le poste de vice-président senior de la stratégie médicale chez Eyetech Pharmaceuticals, où il a joué un rôle clé dans le développement de Macugen®, le premier inhibiteur de VEGF-A approuvé pour des conditions oculaires spécifiques.
Cette nomination intervient alors qu'Aviceda se prépare à faire avancer AVD-104 dans des essais décisifs pour l'atrophie géographique, en utilisant leur plateforme de nanotechnologie propriétaire High Affinity Ligands of Siglecs (HALOS™), visant à atténuer l'inflammation chronique et non résolutive.
Aviceda Therapeutics, ein biopharmazeutisches Unternehmen in der klinischen Phase, hat Dr. Emmett T. Cunningham Jr. in seinen Vorstand berufen. Dr. Cunningham bringt über 20 Jahre Erfahrung als Arzt-Wissenschaftler, Gesundheitsunternehmer und Investor mit, zuvor war er Senior Managing Director bei Blackstone Group.
Im Laufe seiner Karriere hat Dr. Cunningham zur FDA-Zulassung von zehn Therapeutika beigetragen, einschließlich bemerkenswerter ophthalmologischer Behandlungen. Zuvor war er Senior Vice President für medizinische Strategien bei Eyetech Pharmaceuticals, wo er eine Schlüsselrolle bei der Entwicklung von Macugen®, dem ersten VEGF-A-Hemmer, der für spezifische Augenkrankheiten zugelassen wurde, spielte.
Die Ernennung erfolgt, während Aviceda sich darauf vorbereitet, AVD-104 in entscheidende Studien für geografische Atrophie voranzutreiben, wobei sie ihre proprietäre High Affinity Ligands of Siglecs (HALOS™) Nanotechnologie-Plattform nutzen, die darauf abzielt, chronische, nicht lösende Entzündungen zu lindern.
- Appointment of highly experienced board member with track record in FDA approvals
- Strategic expertise in ophthalmology drug development and commercialization
- Progress toward pivotal trials for lead drug candidate AVD-104
- Company still in clinical-stage with no approved products
- Dependent on successful progression of AVD-104 trials
Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment career, Dr. Cunningham has led or co-led financings that contributed to the FDA approval of ten therapeutics, including ophthalmic treatments such as Xiidra®, Rhopressa®, Rocklatan®, Syfovre®, and Izervay®.
He previously served as Senior Vice President of Medical Strategy at Eyetech Pharmaceuticals, where he played a leadership role in the development of Macugen® (pegaptanib sodium), the first VEGF-A inhibitor approved for neovascular age-related macular degeneration and diabetic macular edema. Prior to Eyetech, Dr. Cunningham held clinical development and licensing roles at Pfizer, focused on central nervous system and ophthalmology assets.
“Emmett’s extensive background in science, medicine, and strategic investing, particularly within ophthalmology, adds significant depth to our Board at a time of meaningful momentum for Aviceda,” said Jeffrey Nau, Ph.D., M.M.S., President and Chief Executive Officer of Aviceda Therapeutics. “His unique combination of clinical insight, biopharma operating experience, and investment leadership will be instrumental as we advance AVD-104 into pivotal trials for geographic atrophy and continue to build a leading immunology platform.”
“Aviceda is advancing a scientifically compelling approach to immunomodulation that directly addresses longstanding challenges in ophthalmology,” said Dr. Cunningham. “The potential of the HALOS™ platform, beginning with AVD-104, extends beyond current treatment paradigms. I look forward to contributing to the company’s efforts to translate their innovative approaches into meaningful outcomes for patients with serious, underserved diseases.”
Dr. Cunningham currently serves on the Boards of Eyconis, Oryon Cell Therapies, Nacuity Pharmaceuticals, and InflammX Therapeutics, and has held board positions at more than a dozen innovative biopharma companies, including Annexon Biosciences (NASDAQ: ANNX), GrayBug Vision (NASDAQ: GRAY), Lumos Pharma (NASDAQ: LUMO), SARcode Biosciences (acquired by Shire), Galera Therapeutics (GRTX) and the SFJ Pharmaceutical Group. He is also the founder and former chairman of the Ophthalmology Innovation Summit (OIS), a long-standing platform that brings together leaders in ophthalmic science, innovation, and investment.
Dr. Cunningham is an internationally recognized expert in ocular inflammatory and infectious disease, with more than 400 co-authored publications. He earned an M.D. and M.P.H. in epidemiology and statistics from Johns Hopkins University, and a Ph.D. in neuroscience from the University of
About Aviceda Therapeutics and AVD-104
Aviceda is a private, clinical-stage biotechnology company located in
AVD-104 is an intravitreal glycan-coated nanoparticle with a dual mechanism of action that modulates critical inflammatory cellular and complement pathways through 1) direct deactivation of inflammatory microglia/macrophages’ phagocytic activity and repolarization of these activated microglia/macrophages to their healing state and 2) inhibition of complement cascade amplification.
Along with AVD-104, Aviceda has a broad pipeline of products in development in ophthalmology and multiple other therapeutic areas, including immunology, fibrosis, oncology, and neurology.
Visit the company website to learn more about Aviceda Therapeutics and follow the company on LinkedIn and X (formerly Twitter).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250409496616/en/
Media Contact
Priyanka Shah
Elephant Head Communications
Email: PShah@elephantheadcommunicationsllc.com
Phone: 908-447-6134
Source: Aviceda Therapeutics
FAQ
What is the significance of Dr. Cunningham's appointment to Aviceda Therapeutics' Board?
What is Aviceda's main drug candidate and its target condition?
What is Dr. Cunningham's experience with ophthalmic treatments?
What is Aviceda's HALOS™ technology platform?
